Form 4: Nuvation Bio Inc. Director Acquires Stock Options
SEC Form 4 Filing
Kim D.lickenstaff, a director of Nuvation Bio Inc., acquired stock options for 200,801 shares of Class A Common Stock on September 3, 2024.
Summary
- On September 3, 2024, Kim D.lickenstaff, a director at Nuvation Bio Inc., acquired stock options.
- The options are for 200,801 shares of Class A Common Stock.
- The exercise price of the options is $2.98.
- The options vest on the earlier of September 3, 2025, or the next shareholder annual meeting, contingent upon continuous service.
- The options expire on September 2, 2034.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock option grants, and it doesn't inherently convey positive or negative sentiment. It's a neutral event in terms of investment sentiment.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment as it indicates confidence from a director.
Key Dates
| Date | Description |
|---|---|
| 09/03/2024 | Date of the stock option grant and transaction. |
| 09/03/2025 | One-year anniversary of the grant date; potential vesting date. |
| 09/02/2034 | Expiration date of the stock options. |
| 09/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.